The search for brain-permeant NKCC1 inhibitors for the treatment of seizures: Pharmacokinetic-pharmacodynamic modelling of NKCC1 inhibition by azosemide, torasemide, and bumetanide in mouse brain.
Brain capillary endothelial cells
CNS disorders
Epilepsy
Neonatal seizures
Torsemide
Journal
Epilepsy & behavior : E&B
ISSN: 1525-5069
Titre abrégé: Epilepsy Behav
Pays: United States
ID NLM: 100892858
Informations de publication
Date de publication:
01 2021
01 2021
Historique:
received:
05
10
2020
accepted:
30
10
2020
pubmed:
7
12
2020
medline:
20
4
2021
entrez:
6
12
2020
Statut:
ppublish
Résumé
Because of its potent inhibitory effect on the Na
Identifiants
pubmed: 33279441
pii: S1525-5050(20)30796-4
doi: 10.1016/j.yebeh.2020.107616
pii:
doi:
Substances chimiques
Sodium Potassium Chloride Symporter Inhibitors
0
Solute Carrier Family 12, Member 2
0
Sulfanilamides
0
Bumetanide
0Y2S3XUQ5H
azosemide
MR40VT1L8Z
Torsemide
W31X2H97FB
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
107616Informations de copyright
Copyright © 2020 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest The authors declare that there is no conflict of interest.